French drugmaker Sanofi announced that it has received the CE Mark Approval for its reusable insulin pen called JuniorSTAR.
The pen comes with half unit dosing increment and has been developed for children and teenagers between six and 18 years of age who are suffering from Type-1 diabetes. The pen can work with Lantus (insulin glargine), Apidra (insulin glulisine) or Insuman (recombinant human insulin) and can deliver between 1 to 30 units per injection and has a single-step dial back.
Advertisement"Everyone deserves high-quality care while learning to manage their diabetes, for the best chances in life. With JuniorSTAR, we aim to meet the needs of type 1 patients worldwide, specifically the younger ones, who need an easy-to-use pen device." This is a welcome addition to our comprehensive portfolio of established insulins, which leads the way in personalized diabetes care', the Senior Vice President, Global Diabetes, Sanofi, Pierre Chancel said.
P Paternity Leave Linked to Positive Effect on Childs Cognitive Development Physician Job Satisfaction Driven by High Quality Health Care M
You May Also Like